

# HIV & Cardiovascular Disease

## *Bibliography of One Hundred Key Papers*

selected by **Steven E. Lipshultz\***, MD; **Stacy D. Fisher†**, MD  
**Tracy L. Miller\***, MD; **Tanvi S. Sharma\***, MD; **Angela N. Milton\***, BS

\*Department of Pediatrics - University of Miami Miller School of Medicine and Holtz Children's Hospital  
of the University of Miami-Jackson Memorial Medical Center - Miami, Fla - USA

†Mid-Atlantic Cardiovascular Associates - Baltimore, Md - USA

- 
- |   |   |
|---|---|
| <b>Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE.</b> | <i>Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome.</i><br><b>J Am Coll Cardiol.</b> 2003;41:1598-1605.   |
| <hr/>   |   |
| <b>Ambrose JA, Gould RB, Kurian DC, et al.</b>              | <i>Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection.</i><br><b>Am J Cardiol.</b> 2003;92:301-303.   |
| <hr/>   |   |
| <b>Bestetti RB, Figueiredo JF, Da Costa JC.</b>             | <i>Salmonella tricuspid endocarditis in an intravenous drug abuser with human immunodeficiency virus infection.</i><br><b>Int J Cardiol.</b> 1991;30:361-362.   |
| <hr/>   |   |
| <b>Blanchard DG, Hagenhoff C, Chow LC, et al.</b>           | <i>Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study.</i><br><b>J Am Coll Cardiol.</b> 1991;17:1270-1276.                   |
| <hr/>   |   |
| <b>Boccarda F, Teiger E, Cohen A, et al.</b>                | <i>Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis.</i><br><b>Heart.</b> 2006;92:543-544.  |
| <hr/>   |   |
| <b>Bozzette S, Ake CF, Tam HK, Chang SW, Louis TA.</b>      | <i>Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.</i><br><b>N Engl J Med.</b> 2003;348:702-710.  |
| <hr/>   |   |
| <b>Bruno R, Sacchi P, Filice G.</b>                         | <i>Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy.</i><br><b>AIDS.</b> 2003;17:S83-S87. |
| <hr/>   |   |
| <b>Calabrese LH.</b>  | <i>Vasculitis and infection with the human immunodeficiency virus.</i><br><b>Rheum Dis Clin North Am.</b> 1991;17:131-147.  |
| <hr/>   |   |
| <b>Carr A, Samaras K, Burton S, et al.</b>                  | <i>A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.</i><br><b>AIDS.</b> 1998;12:F51-F58.   |
| <hr/>   |   |
| <b>Carr A, Samaras K, Thorisdottir A, et al.</b>            | <i>Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study.</i><br><b>Lancet.</b> 1999;353:2093-2099.           |
-

**Bibliography of One Hundred Key Papers**

---

- Carrillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH.** *Brain natriuretic peptide and HIV-related cardiomyopathy.* **AIDS Read.** 2002;12:501-503, 508.
- 
- Cea-Calvo L, Escribano Subias P, Tello De Menesses R, et al.** *Treatment of HIV-associated pulmonary hypertension with treprostinil [in Spanish].* **Rev Esp Cardiol.** 2003;56:421-425.
- 
- Cheitlin MD.** *Cardiovascular complications of HIV. In: Sande MA, Volberding PA, eds.* **The Medical Management of AIDS.** 5th ed. Philadelphia, Pa: WB Saunders; 1997:247-256.
- 
- Chetty R.** *Vasculitides associated with HIV infection.* **J Clin Pathol.** 2001;54:275-278.
- 
- Correia D, Rodrigues De Resende LA, Molina RJ, et al.** *Power spectral analysis of heart rate variability in HIV-infected and AIDS patients.* **Pacing Clin Electrophysiol.** 2006;29:53-58.
- 
- Cupler EJ, Danon MJ, Jay C, et al.** *Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.* **Acta Neuropathol (Berl).** 1995;90:1-6.
- 
- Currie PF, Boon NA.** *Immunopathogenesis of HIV-related heart muscle disease: current perspectives.* **AIDS.** 2003;17:S21-S28.
- 
- Currie PF, Goldman JH, Caforio AL, et al.** *Cardiac autoimmunity in HIV related heart muscle disease.* **Heart.** 1998;79:599-604.
- 
- Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA.** *Heart muscle disease related to HIV infection: prognostic implications.* **BMJ.** 1994;309:1605-1607.
- 
- Currie PF, Sutherland GE, Jacob AJ, et al.** *A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection.* **Eur Heart J.** 1995;16:15-18.
- 
- de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA.** *Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients.* **Blood Coagul Fibrinolysis.** 2003;14:15-18.
- 
- Detels R, Munoz A, McFarlane G, et al.** *Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.* **JAMA.** 1998;280:1497-503.
- 
- Dube MP, Stein JH, Aberg JA, et al.** *Guideline for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group.* **Clin Infect Dis.** 2003;37:613-627.
- 
- Duong M, Dubois C, Buisson M, et al.** *Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus.* **Clin Cardiol.** 1997;20:497-502.
-



- 
- Eisenhauer MD, Eliasson AH, Taylor AJ, et al.** *Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients.*  
**Chest.** 1994;105:389-395.
- 
- Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J.** *Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.*  
**Eur J Pediatr.** 2007;166:13-21.
- 
- Fisher SD, Bowles NE, Towbin JA, Lipshultz SE.** *Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes.*  
**AIDS.** 2003;17:S29-S35.
- 
- Fisher SD, Easley KA, Orav EJ, et al.** *Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P<sup>2</sup>C<sup>2</sup> HIV Multicenter Study.*  
**Am Heart J.** 2005;150:439-447.
- 
- Fisher SD, Lipshultz SE.** *Cardiovascular disease in HIV-infected individuals.*  
In: Braunwald E, ed.  
**Heart Disease: A Textbook of Cardiovascular Medicine.** 6th ed. Philadelphia, Pa: WB Saunders Co; 2000;(chap 68):2211-2222.
- 
- Fisher SD, Lipshultz SE.** *Epidemiology of cardiovascular involvement in HIV disease and AIDS.*  
**Ann N Y Acad Sci.** 2001;946:13-22.
- 
- Fisher SD, Lipshultz SE.** *Cardiac disease.* In: Dolin R, Masur H, Saag MS, eds.  
**AIDS Therapy.** 2nd ed. New York, NY: Churchill Livingstone; 2003:814-826.
- 
- Fisher SD, Miller TL, Lipshultz SE.** *Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.*  
**Atherosclerosis.** 2006;185:1-11.
- 
- Frater RW, Sisto D, Condit D.** *Cardiac surgery in human immunodeficiency virus (HIV) carriers.*  
**Eur J Cardiothorac Surg.** 1989;3:146-150.
- 
- Freeman R, Roberts MS, Friedman LS, et al.** *Autonomic function and human immunodeficiency virus infection.*  
**Neurology.** 1990;40:575-580.
- 
- Frerichs FC, Dingemans KP, Brinkman K.** *Cardiomyopathy with mitochondrial damage associated with nucleoside reverse transcriptase inhibitors.*  
**N Engl J Med.** 2002;347:1895-1896.
- 
- Friis-Møller N, Sabin CA, Weber R, et al.** *Combination antiretroviral therapy and the risk of myocardial infarction.*  
**N Engl J Med.** 2003;349:1993-2003.
- 
- Friis-Møller N, Weber R, Reiss P, et al.** *Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study.*  
**AIDS.** 2003;17:1179-93.
- 
- Gluck T, Degenhardt E, Scholmerich J, Lang B, Grossmann J, Straub RH.** *Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication.*  
**Clin Auton Res.** 2000;10:17-22.
-

**Bibliography of One Hundred Key Papers**

---

<b>Gottlieb S.</b>	<i>Antiretroviral therapy increases risk of heart attack.</i> <b>BMJ.</b> 2003;327:1186.
<b>Grinspoon S, Carr A.</b>	<i>Cardiovascular risk and body-fat abnormalities in HIV-infected adults.</i> <b>N Engl J Med.</b> 2005;352:48-62.
<b>Hadigan C, Meigs JB, Wilson PW, et al.</b>	<i>Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution.</i> <b>Clin Infect Dis.</b> 2003;36:909-916.
<b>Harmon WG, Dadlani GH, Fisher SD, Lipshultz SE.</b>	<i>Myocardial and pericardial disease in HIV.</i> <b>Curr Treat Options Cardiovasc Med.</b> 2002;4:497-509.
<b>Hebert VY, Crenshaw BL, Romanoff RL, et al.</b>	<i>Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation.</i> <b>Cardiovasc Toxicol.</b> 2004;4:117-132.
<b>Heidenreich PA, Eisenberg MJ, Kee LL, et al.</b>	<i>Pericardial effusion in AIDS. Incidence and survival.</i> <b>Circulation.</b> 1995;92:3229-3234.
<b>Henry K, Melroe H, Huebsch J, et al.</b>	<i>Severe premature coronary artery disease with protease inhibitors.</i> <b>Lancet.</b> 1998;351:1328.
<b>Herskowitz A, Willoughby SB, Vlahov D, Baughman KL, Ansari AA.</b>	<i>Dilated heart muscle disease associated with HIV infection.</i> <b>Eur Heart J.</b> 1995;16(suppl O):50-55.
<b>Himelman RB, Dohrmann M, Goodman P, et al.</b>	<i>Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome.</i> <b>Am J Cardiol.</b> 1989;64:1396-1399.
<b>Holmberg SD, Moorman AC, Williamson JM, et al.</b>	<i>Protease inhibitors and cardiovascular outcomes in patients with HIV-1.</i> <b>Lancet.</b> 2002;360:1747-1748.
<b>Jenson HB, Pollock BH.</b>	<i>Cardiac cancers in HIV-infected patients. In: Lipshultz SE, ed. <b>Cardiology in AIDS.</b> New York, NY: Chapman &amp; Hall; 1998:255-263.</i>
<b>Kamin DS, Grinspoon SK.</b>	<i>Cardiovascular disease in HIV positive patients.</i> <b>AIDS.</b> 2005;19:641-652.
<b>Kearney DL, Perez-Atayde AR, Easley KA, et al.</b>	<i>Postmortem cardiomegaly and echocardiographic measurements of left ventricular size and function in children infected with the human immunodeficiency virus. The Prospective P<sup>2</sup>C<sup>2</sup> HIV Multicenter Study.</i> <b>Cardiovasc Pathol.</b> 2003;12:140-148.
<b>Klein D, Hurley LB, Quesenberry CP Jr, Sidney S.</b>	<i>Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?</i> <b>J Acquir Immune Defic Syndr.</b> 2002;30:471-477.
<b>Kwan T, Karve MM, Emerole O.</b>	<i>Cardiac tamponade in patients infected with HIV. A report from an inner-city hospital.</i> <b>Chest.</b> 1993;104:1059-1062.
<b>Lai WW, Lipshultz SE, Easley KA, et al; P<sup>2</sup>C<sup>2</sup> HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</b>	<i>Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus infected women: the prospective P<sup>2</sup>C<sup>2</sup> HIV Multicenter Study.</i> <b>J Am Coll Cardiol.</b> 1998;32:1749-1755.



- 
- Langston C, Cooper ER, Goldfarb J, et al.** *Human immunodeficiency virus–related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P<sup>2</sup>C<sup>2</sup>) Study.* **Pediatrics.** 2001;107:328-338.
- 
- Lamperth L, Dalakas MC, Dagani F, et al.** *Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model.* **Lab Invest.** 1991;65:742-751.
- 
- Lipshultz SE, Easley KA, Orav EJ, et al.** *Absence of cardiac toxicity of zidovudine in infants.* **N Engl J Med.** 2000;343:759-766.
- 
- Lipshultz SE, Easley KA, Orav EJ; Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group.** *Cardiac dysfunction and mortality in HIV-infected children. The prospective P<sup>2</sup>C<sup>2</sup> HIV multicenter study.* **Circulation.** 2000;102:1542-1548.
- 
- Lipshultz SE, Easley KA, Orav J, et al.** *Left ventricular structure and function in children infected with human immunodeficiency virus. The Prospective P<sup>2</sup>C<sup>2</sup> HIV Multicenter Study.* **Circulation.** 1998;97:1246-1256.
- 
- Lipshultz SE, Easley KA, Orav EJ, et al; P<sup>2</sup>C<sup>2</sup> HIV Study Group.** *Cardiovascular status of infants and children of women infected with HIV-1 (P<sup>2</sup>C<sup>2</sup> HIV): a cohort study.* **Lancet.** 2002;360:368-373.
- 
- Lipshultz SE, Fisher SD, Lai W, Miller TL.** *Cardiac monitoring and therapy for HIV-infected patients.* **Ann N Y Acad Sci.** 2001;946:236-273.
- 
- Lipshultz SE, Fisher SD, Lai WW, Miller TL.** *Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients.* **AIDS.** 2003;17(suppl 1):S96-S122.
- 
- Lipshultz SE, Orav EJ, Sanders SP, et al.** *Immunoglobulins and left ventricular structure and function in pediatric HIV infection.* **Circulation.** 1995;92:2220-2225.
- 
- Lipshultz SE, Orav EJ, Sanders SP, Rubin A, McIntosh K, Colan SD.** *Abnormalities of cardiac structure and function in HIV-infected children treated with zidovudine.* **N Engl J Med.** 1991;327:1260-1265.
- 
- Lopez JA, Ross RS, Fishbein MC, Siegel RJ.** *Nonbacterial thrombotic endocarditis: a review.* **Am Heart J.** 1987;113:773-784.
- 
- Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE.** *Cardiac morbidity and related mortality in children with HIV infection.* **JAMA.** 1993;269:2869-2875.
- 
- Manavi K.** *A review on infection with human immunodeficiency virus.* **Best Pract Res Clin Obstet Gynaecol.** 2006;20:923-940.
- 
- Mary-Krause M, Cotte L, Simon A, et al.** *Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.* **AIDS.** 2003;17:2479-2486.
- 
- Miller TL, Easley KA, Zhang W, et al.** *Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P<sup>2</sup>C<sup>2</sup> human immunodeficiency virus multicenter study.* **Pediatrics.** 2001;108:1287-1296.
-

**Bibliography of One Hundred Key Papers**

---

- Miller TL, Orav EJ, McIntosh K, Colan S, Lipshultz SE.** *Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus.*  
**Am J Clin Nutr.** 1997;66:660-664.
- 
- Mittal CM, Wig N, Mishra S, Deepak KK.** *Heart rate variability in human immunodeficiency virus-positive individuals.*  
**Int J Cardiol.** 2004;94:1-6.
- 
- Moorthy LN, Lipshultz SE.** *Cardiovascular monitoring of HIV-infected patients.*  
*In: Lipshultz SE, ed.*  
**Cardiology in AIDS.** New York, NY; Chapman & Hall; 1998:345-386.
- 
- Mooser V.** *Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease?*  
**AIDS.** 2003;17:S65-S69.
- 
- Moreno R, Villacastin JP, Bueno H, et al.** *Clinical and echocardiographic findings in HIV patients with pericardial effusion.*  
**Cardiology.** 1997;88:397-400.
- 
- Morse CG, Kovacs JA.** *Metabolic and skeletal complications of HIV infection: the price of success.*  
**JAMA.** 2006;296:844-854.
- 
- Nahass RG, Weinstein MP, Bartels J, Gocke DJ.** *Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients.*  
**J Infect Dis.** 1990;162:967-970.
- 
- Nanavati KA, Fisher SD, Miller TL, Lipshultz SE.** *HIV-related cardiovascular disease and drug interactions.*  
**Am J Cardiovasc Drugs.** 2004;4:315-324.
- 
- Nordin C, Kohli A, Beca S, et al.** *Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients.*  
**J Electrocardiol.** 2006;39:199-205.
- 
- Nunes H, Humbert M, Sitbon O, et al.** *Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.*  
**Am J Respir Crit Care Med.** 2003;167:1433.
- 
- Periard D, Telenti A, Sudre P, et al.** *Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.*  
**Circulation.** 1999;100:700-705.
- 
- Piscitelli SC, Gallicano KD.** *Drug therapy: Interactions among drugs for HIV and opportunistic infections.*  
**N Engl J Med.** 2001;344:984-996.
- 
- Pugliese A, Isnardi D, Saini A, et al.** *Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement.*  
**J Infect.** 2000;40:282-284.
- 
- Rangasetty UC, Rahman AM, Hussain N.** *Reversible right ventricular dysfunction in patients with HIV infection.*  
**South Med J.** 2006;99:274-278.
- 
- Roland ME, Havlir DV.** *Responding to organ failure in HIV-infected patients.*  
**N Engl J Med.** 2003;348:2279-2280.
-



- 
- Saidi A, Bricker JT.** *Pulmonary hypertension in patients infected with HIV.*  
In: Lipshultz SE, ed.  
**Cardiology in AIDS.** New York, NY: Chapman & Hall; 1998:187.
- 
- Sani MU, Okeahialam BN.** *QTc interval prolongation in patients with HIV and AIDS.*  
**J Natl Med Assoc.** 2005;97:1657-1661.
- 
- Schambelan M, Benson CA, Carr A, et al.** *Management of metabolic complications associated with anti-retroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.*  
**J Acquir Immune Defic Syndr.** 2002;31:257-275.
- 
- Seoane L, Shellito J, Welsh D, et al.** *Pulmonary hypertension associated with HIV infection.*  
**South Med J.** 2001;94:635-639.
- 
- Shearer WT, Lipshultz SE, Easley KA, et al.** *Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors.*  
**Pediatrics.** 2000;105:e9.
- 
- Silver MA, Macher AM, Reichert CM, et al.** *Cardiac involvement by Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS).*  
**Am J Cardiol.** 1984;53:983-985.
- 
- Sitbon O, Gressin V, Speich R, et al.** *Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.*  
**Am J Respir Crit Care Med.** 2004;170:1212-1217.
- 
- Starc TJ, Lipshultz SE, Easley KA, et al.** *Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P<sup>2</sup>C<sup>2</sup> HIV study.*  
**J Pediatr.** 2002;141:327-334.
- 
- Starc TJ, Lipshultz SE, Kaplan S, et al.** *Cardiac complications in children with human immunodeficiency virus infection. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P<sup>2</sup>C<sup>2</sup> HIV) study group, National Heart, Lung, and Blood Institute.*  
**Pediatrics.** 1999;104:e14.
- 
- Stein JH, Klein MA, Bellehumeur JL, et al.** *Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.*  
**Circulation.** 2001;104:257-262.
- 
- Sudano I, Spieker LE, Noll G, et al.** *Cardiovascular disease in HIV infection.*  
**Am Heart J.** 2006;151:1147-1155.
- 
- Thoni GJ, Fedou C, Brun JF, et al.** *Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia.*  
**Diabetes Metab.** 2002;28:397-404.
- 
- Trautner BW, Darouiche RO.** *Tuberculous pericarditis: optimal diagnosis and management.*  
**Clin Infect Dis.** 2001;33:954-961.
- 
- Vittecoq D, Escaut L, Chironi G, et al.** *Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era.*  
**AIDS.** 2003;17(suppl 1):S70-S76.
-

**Bibliography of One Hundred Key Papers**

**Volberding PA, Murphy RL, Barbaro G, et al**

*The Pavia consensus statement.*  
**AIDS.** 2003;17:S170-S179.

---

**Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M.**

*Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.*  
**J Infect Dis.** 2002;185:456-462.

---

**Zareba KM, Miller TL, Lipshultz SE.**

*Cardiovascular disease and toxicities related to HIV infection and its therapies.*  
**Expert Opin Drug Saf.** 2005;4:1017-1025.

---